“Pete is the perfect person to create deep insights that optimize Knownwell’s ability to help customers navigate AI transformation,” said CEO David DeWolf. “He’s the rare breed of executive who sees the business big picture better than anyone I know, while also excelling at framing, teaching, and simplifying this vision for customers. I’m confident Pete’s knowledge and experience will be huge assets for Knownwell and our clients as we scale the company.”
Prior to joining Knownwell, Buer spent close to three decades at CEB, now Gartner. He held multiple Executive Committee and C-Level roles at CEB, helping to build the business as line executive launching and running the company’s practice for Sales and Marketing Executives, and helping to scale the business in such central roles such as Chief Culture Officer and Chief Administrative Officer/Head of HR. Buer was also Chief of People and Operations at 3Pillar Global, the product development company founded by Knownwell CEO David DeWolf, and Chief Growth Officer at Brightfield, a venture-backed extended workforce intelligence company with a proprietary AI platform called TDX.
About Knownwell
Knownwell is an AIaaS and advisory solutions company specializing in helping executives leverage the AI revolution to drive record profitability without compromising their people or values. Knownwell’s proprietary maturity model and related advisory services provide executives of private-equity backed companies with the knowledge and know-how to leverage AI as a key differentiator. Please visit knownwell.com to learn more about the company.
Nonprofits face unique challenges grappling with multiple plug-ins:
Resource Limitations: Nonprofits frequently operate with limited staff and constrained budgets, making plug-in management expenses a liability they can’t easily afford.
Complexity Complications: The intricacies of handling multiple plug-ins can be overwhelming and pull limited staff away from their core responsibilities that actually contribute to the cause.
Jeopardizing the Mission: For nonprofit organizations counting on every donor and dollar, diverting money away from those in need toward troubleshooting inefficient processes can have undesirable consequences for the overall mission.
Altruism is alive and well; however, reaching out to new donors and managing existing ones remains beset with challenges, such as insufficient resources, changes in regulation, the complexities of tracking donations, and fractured omnichannel engagement. Prospective donors usually require 7 to 12 “touches” before becoming donors, such as websites, emails, newsletters, direct mail, videos, and social media.(3) Assessing the efficiency, efficacy, and scope of these approaches requires using a platform that integrates multiple channels and provides a detailed evaluation of their tangible results in the fundraising effort.
To retain and acquire new donors, nonprofits need a customized Customer Commerce strategy that builds strong donor relationships with a cost-effective solution that covers CRM, CMS, POS, multi-currency support, API integrations, and omnichannel capabilities.
StoreConnect is the Customer CommerceTM Company and is the only fully integrated eCommerce, point-of-sale, content management system and CRM platform powered by Salesforce. It includes a scalable, feature-rich platform enabling nonprofits to oversee single or recurring monthly donations, memberships, merchandise sales, event reservations, inventory control, and workflow management, along with providing flexible fundraising and donation choices. It strongly emphasizes donor relationships by integrating all content, product, donor, and inventory data into a unified multi-store system that operates seamlessly on mobile devices, the web, and point-of-sale locations. StoreConnect provides all of these features without requiring additional plug-ins, all within a budget aligned with the philanthropic mission of each nonprofit.
“StoreConnect’s Health Check tool reveals what keeps donors engaged and what might deter them. It’s a one-stop platform designed for nonprofits to build personal, lasting bonds with donors, fostering loyalty and sustaining vital contributions to their cherished causes.”
StoreConnect is Time. Well Spent.
About StoreConnect Mikel Lindsaar is the CEO and Founder of StoreConnect, a Salesforce Partner Innovation Award recipient.‥ Mikel is a serial technology entrepreneur, having successfully built and sold four SaaS companies within the last decade. StoreConnect has one goal: to help small and medium-sized businesses become scalable Customer Companies powered by Salesforce. Clients achieve this daily by breaking free of the shackles of what Mikel calls “Plug-in Purgatory and SaaS Hell.” StoreConnect clients don’t need multiple SaaS systems connected by plug-ins to manage their online, in-store POS, and in-person Customer Commerce business systems. Many of today’s eCommerce solutions are designed to get up and running quickly and inevitably hit a brick wall of scalability and extensibility as companies grow.‥ That’s why StoreConnect is built on the world’s #1 CRM, so its customers will never need to re-platform, no matter how fast they grow in size, product offerings, or regions. Global growth now has no barriers for any SMB. Being built on Salesforce allows StoreConnect customers to update their websites, funnels, and content in real-time, providing an unparalleled competitive advantage. StoreConnect is Time. Well Spent. Visit https://getStoreConnect.com/.
References: 1. “Trainings in Nonprofit Fundraising, Proposal Writing, Grants.” Candid Learning, learning.candid.org/resources/knowledge-base/number-of-nonprofits-in-the-u-s/#:~:text=According%20to%20the%20National%20Center,fraternal%20organizations%20and%20civic%20leagues. Accessed 27 Sept. 2023. 2. “StoreConnect Leads the Way in Resolving ‘Plug-in Purgatory’ for SMBS at Dreamforce 2023.” Yahoo! Finance, Yahoo!, finance.yahoo.com/news/storeconnect-leads-way-resolving-plug-120300604.html. Accessed 26 Sept. 2023. 3. Lakshmi Narayanan Lakshmi is a marketer and writer for the CallHub blog. She uses targeted content to help campaign managers (in advocacy groups, et al. “Unable to Raise Funds? These Fundraising Challenges Are Holding You Back.” CallHub, 7 Mar. 2023, callhub.io/blog/fundraising/nonprofit-fundraising-challenges/.
The Leading Home Care Franchise, BrightStar Care Ranks 117 on Franchise Times’ Prestigious Annual List
GURNEE, Ill., Oct. 11, 2023 /PRNewswire-PRWeb/ — BrightStar Care, the nation’s leading home care and medical staffing franchise with more than 380 corporate and independently owned and operated agencies, was recognized as one of the top 400 franchise brands in the county on the Franchise Times Top 400 annual rankings list for 2023.
The Franchise Times Top 400 is an exclusive annual ranking of the largest U.S.-based franchise systems by global systemwide sales. The project is the result of a five-month research and reporting effort that leads to the most credible and objective franchise ranking available, said Franchise Times Editor-in-Chief Laura Michaels. The collection of systemwide sales data also provides useful insight into the franchise industry’s performance as the shakeout continues following the COVID-19 pandemic.
“We are truly honored to once again secure our position on this prestigious annual list of the nation’s top franchises, alongside numerous other esteemed franchise brands,” said Pete First, Chief Development Officer of BrightStar Care. “Our commitment to delivering the higher standard of care to our clients continues, with invaluable support from both our dedicated existing franchisees and enthusiastic newcomers, who collectively contribute to our continued expansion into new markets and territories.”
This year BrightStar Care has seen incredible growth with franchisees expanding the brand footprint into new territories across the United States. Over the last year, BrightStar Care has released groundbreaking data demonstrating the brand’s unmatched clinical outcomes and payer benefits as well as impactful industry studies that benefit and strengthen its entire franchise network. With these achievements, BrightStar Care is well-positioned to continue its accelerated growth trajectory and affirm its spot as a leader in the franchise and home care industries.
ABOUT THE FRANCHISE TIMES TOP 400:
The Franchise Times Top 400 is the only ranking by systemwide sales and units of the largest 500 U.S.-based franchise brands. Published in the October issue and available in a searchable database online, the Franchise Times Top 400 also analyzes industry sectors based on percentage change in sales growth, reports the 10 fastest-growing franchises by four different measures, and includes exclusive news stories about the biggest names in franchising. The rankings and full report, and the searchable online database, are available at www.franchisetimes.com/top-400-2023.
ABOUT BRIGHTSTAR CARE:
BrightStar Care is a national home care and medical staffing franchise headquartered in the Chicagoland area with more than 380 franchised and company-owned locations nationwide that provide medical and non-medical services to clients in their homes, as well as supplemental care staff to corporate clients. BrightStar Care operates under multiple separate revenue streams allowing franchisees uncapped earning potential. Over the last 20 years, Founder and CEO Shelly Sun has built BrightStar Care from a local business into a nationally recognized brand that generates more than $639 million system-wide using a franchise model built for infinite growth. In addition, BrightStar Care is the only national home care franchise to receive The Joint Commission’s Enterprise Champion for Quality award consecutively for more than a decade. Other prestigious BrightStar Care accolades include making the Entrepreneur Franchise 500 list for 13 consecutive years, and continuously ranking on Franchise Business Review’s Top Franchise list and Franchise Times Top 400 list. For more information on BrightStar Care please visit http://www.brightstarfranchising.com.
symplr, a DAISY Foundation™ sponsor, co-produced the Moments that Matter videos with the foundation to showcase nursing excellence at AdventHealth Parker in Colorado, City of Hope in California, and WellStar North Fulton in Georgia.
“Five minutes can make a difference, but sometimes in a day, a nurse doesn’t have five minutes to just sit down with a patient or family,” said Susan Brown, Ph.D., RN, CENP, Senior Vice President of Patient Care Services and Chief Nursing Officer at City of Hope. “Administrative tasks and documentation are the things that take the most time. And that time is usually not at the patient’s bedside.”
“Empowering the nursing workforce with time to change lives is critical” said Dr. Karlene Kerfoot, PhD, RN, FAAN, Chief Nursing Officer of symplr and a DAISY Foundation Board Member. “Our solutions are built with clinicians, for clinicians to reduce administrative tasks, allowing nurses to build trust with patients, enhance outcomes.”
symplr’s second annual Compass Survey found that 84% of respondents believe consolidating healthcare operations software with a single vendor could redirect 10% more time to clinical care, improving patient outcomes, clinician retention, and job satisfaction. Two-thirds of clinicians also indicated their current healthcare operations software provides a difficult user experience. The survey involved CHIME members and other senior healthcare IT leaders.
To learn more about symplr Workforce Solutions being showcased at ANCC- Magnet, visit symplr Nursing solutions.
About symplr symplr is a leader in enterprise healthcare operations software and services. For more than 30 years and with deployments in 9 of 10 U.S. hospitals, symplr has been committed to improving healthcare operations through its cloud-based solutions, driving better operations for better outcomes.
Our provider data management; workforce management; compliance, quality, and safety; and contract, supplier, and spend management solutions improve the efficiency and efficacy of healthcare operations, enabling caregivers to quickly handle administrative tasks so they have more time to do what they do best: provide high-quality patient care. Learn how at symplr.
About the DAISY Foundation The DAISY (Diseases Attacking the Immune System) Foundation is a not-for-profit organization established in memory of J. Patrick Barnes. The compassionate care Patrick and his family received from nurses while he was ill inspired the creation of The DAISY Award® for Extraordinary Nurses, an evidenced-based means of providing nurse recognition wherever they practice, in whatever role they serve, and throughout their careers. The foundation partners with 6,200+ healthcare facilities and schools of nursing internationally and funds nursing research grants and evidence-based practice studies. Visit DaisyFoundation.org.
Media Contact
Madeleine Smith, Matter Health for symplr, 2528146671, [email protected]
Pappas OPT’s CEO, Michael Pappas, PT, DPT expressed great pride in Lauran Weil, stating, “We are immensely proud of Lauren for receiving the prestigious Team Leader of the Year Award. Her dedication to clinic growth and her unwavering commitment to excellence have been instrumental in our success.”
The Rhode Island-based physical therapy group has flourished under Weil’s leadership, experiencing EBITDA growth even during the pandemic, nearly doubling the clinic size, and increasing the number full-time clinical employees. In addition to clinic size and job opportunities, the clinic is experiencing double-digit increases in the number of new visits and number of new patients, demonstrating the power of the Core 4 (news impacts, impacts, intensity of visit, and cancel / no show rate) in outpatient clinics.
“Lauren embodies the values and spirit of both Pappas OPT and Confluent Health,” continued Pappas, “and we congratulate her on this well-deserved honor.”
Confluent Health’s CEO, Kristi Henderson, DNP, FAAN, also commended Weil’s outstanding leadership, saying, “Lauren Weil’s exceptional leadership, dedication to her team, and outstanding clinical skills exemplify the qualities we celebrate with the Team Leader of the Year Award. She sets a high standard for clinical excellence and embodies the spirit of Confluent Health’s mission to transform healthcare, Congratulations to Lauren on this remarkable achievement.”
Lauren Weil’s accomplishments and dedication to her profession make her a true role model within the healthcare industry. Confluent Health is honored to recognize her as the 2023 Team Leader of the Year.
About Pappas OPT Physical, Sports and Hand Therapy Pappas | OPT Physical, Sports and Hand Therapy (POPT) is a Rhode Island-based, private physical therapy practice group. As a proud member of the Confluent Health family, POPT positively impacts patients’ lives by delivering the best care and results through proven research, innovative treatments and technologies, and an approach that treats patients like family. For more information, visit pappasopt.com, or find them on Facebook at @pappaspt or @optphysicaltherapy.
About Confluent Health Confluent Health is a family of physical and occupational therapy companies. We are transforming healthcare by strengthening private practices, developing highly effective clinicians, innovating new services and technology to improve the quality of care for patients, and lowering costs via more effective treatment, workplace wellness, and injury prevention. For more information, visit goconfluent.com or find us on Facebook at @confluenthealth.
“This little book is perhaps the closest I have ever come to being able to say, ‘I have only written what I heard the Father say,'” said Parsons Eiland.
Sandra Parsons Eiland is a naturopathic doctor from Missouri, residing in Texas. She has been a licensed minister and home missionary with FGEA (Full Gospel Evangelistic Association), for which she also wrote several kid’s corner pages that were sent out to their entire membership.
Xulon Press, a division of Salem Media Group, is the world’s largest Christian self-publisher, with more than 20,000 titles published to date. Jerry’s New Friend is available online through xulonpress.com/bookstore, amazon.com, and barnesandnoble.com.
Media Contact
Sandra Parsons Eiland, Salem Author Services, 407-339-4217, sjeiland55@gmail.com
In August 2022, the U.S. Congress passed the Inflation Reduction Act (IRA) to reduce the cost of prescription drugs borne by patients. While many individuals certainly benefited from the legislation, the 30 million Americans suffering from rare diseases seem to have been left on the wayside.3
Due to the act’s provision that allows certain FDA-approved drugs, including those targeting multiple diseases and small molecule medicines, to be eligible for price negotiation after just seven years, one can anticipate a sustained slowdown in drug development and innovation. This stagnation is expected to be especially acute in rare disease research, as the field relies extensively on experimentation with repurposed drugs and small-molecule medicine to achieve medical advancements.
Alnylam Pharmaceuticals Inc., for example, halted its research on Stargadt treatment in October 2022, explicitly attributing the pause to the IRA.4 As Alnylam was basing its treatment on a drug that was approved to treat a different condition, the resulting cure would have been subject to price renegotiation.
Since its enactment, the IRA has sent shockwaves across the world. Given that the U.S. plays a prominent role in biopharmaceutical research, the abrupt restrictions imposed by the IRA present a major setback to the global battle against rare diseases.
New hurdles on the horizon for India and the Indian Diaspora
One country that is likely to bear the brunt of the deceleration in rare disease research is India, a long-standing partner of the U.S. in this field. With 70 to 96 millions living with rare diseases,5 many of which are unique to the Indian subcontinent, India has its hands full managing these conditions.
The Indian government has a great start in 2021 with the Ministry of Health and Family Welfare formulating and adopting a National Policy for Rare Diseases (NPRD) that includes a one-time treatment subsidy of USD 61,000 per patient. The program initially promises to be accessible to 40% of the population and has since established over 11 diagnostic and treatment centers of excellence across the country.6
However, this program needs significant expansion to cover all 10,867 (and growing) known rare diseases and not just those small number of currently treatable rare diseases. The policy currently only covers persons afflicted by a subset of the 450 recognized rare diseases. The implementation of NPRD will also need to at least triple the number of centers of excellence to meet the needs of the entire rare disease population of India and provide more accessibility across the country including the rural population. As for the diagnostic and treatment centers, their impact is currently hampered by the absence of formal referral channels established between primary care, secondary care, and tertiary care centers, which hinders patient access.
“A national policy with funding is a great start but is insufficient to cover the treatment of many rare diseases as orphan drugs have to be imported into India,” says Dr. Harsha Rajasimha, founder and executive chairperson of IndoUSrare, a nonprofit centered on combating rare diseases through cross-border collaborations. “Furthermore, many known rare conditions in the U.S. such as ALS (also known as Lou Gehrig’s disease or motor neuron disease (MND)), ultra rare indications caused by single gene mutations such as ADSSL1, DLG4, MNGIE, VCP, and SYNGAP, are not officially recognized by NPRD, thus leaving over 90% of the rare diseases on the fence. Thousands of rare diseases fall under the realm of genomics, precision medicine, patient registries, and clinical research. This is where IndoUSrare seeks to collaborate with the GoI, patient groups, and industry stakeholders to foster cross-border collaborations to accelerate research and clinical trials.” Says Dr. Rajasimha who has also pioneered an intelligent technology platform for efficient implementation of patient registries and clinical trials.
The call for more inclusive research and clinical trials
Considering the rare disease research slowdown in the U.S. and the growing concerns about these disorders in India, increased Indo-US collaboration, particularly in the context of clinical trials, can help mitigate consequences.
The U.S. conducts nearly half of the global clinical trials for rare diseases. However, these trials are not representative of the country’s ethnic makeup, underrepresenting many diasporas, Indian included. For example, despite India having one-third of all rare disease cases worldwide, only nine of the 202 trials registered in the U.S. were conducted there. Participation of the Indian diaspora in these trials is hardly better; in the 193 trials that did not take place in India, only 1% of participants were of Indian origin.7
This lack of representation in clinical trials is problematic because it raises questions about the applicability of the findings; different patient groups may respond differently to identical treatments. This is relevant for specific Indian demographics, as their long history of genetic isolation and unique cultural practices may shape the way they respond to treatments.
By failing to capture the ethnic diversity within the U.S., these non-representative clinical trials may not only lead to a misinterpretation of treatment effects on American rare disease patients but also impede India’s efforts due to the absence of Indian participants. Indeed, considering the additional costs associated with conducting clinical trials in India, Indian regulators have in the past waived the requirement for representative trials if the orphan treatment has already been approved by the U.S. Food and Drug Administration. Consequently, Indian patients may at times receive treatments may be ineffective for them.
“Without a diverse base of study participants, researchers lack representative data on disease progression and research efficacy,” says Frank Sasinowski, MS, MPH, JD, Director at Hyman Phelps McNamara P.C., and Founding Board Member of IndoUSrare.
The need for more inclusive clinical trials is timely because it provides both the U.S. and India with an opportunity to deepen their understanding of the rare diseases affecting both countries — even under the clamping effect of the IRA. Cross-border initiatives, such as those focused on research digitization, data sharing, and the creation of patient registries, can increase the participation of Indian patients as well as those from other groups in these trials.
Coming to a head in the Bridging RARE Summit 2023
Though the U.S. deserves to be congratulated on the 40th anniversary of the Orphan Drug Act of 1983, recent policy changes such as the IRA have stifled biopharmaceutical innovation in the field of rare diseases. This shift is poised to exacerbate India’s struggles in addressing these disorders as it endeavors to improve access to orphan drugs and advance rare disease research and treatment.
One way for both countries to alleviate the fallout resulting from the IRA is to invoke their trusted biopharmaceutical partnership. Collaborative research efforts can expedite the development of treatments, expand their accessibility to regions in pressing need, and pave the way for more inclusive clinical trials.
The intricacies of managing rare diseases, including challenges and potential solutions, will be explored in greater depth during the two-day Bridging RARE Summit 2023. Join the host, IndoUSrare, alongside representatives from the rare disease community, on October 29-30 in this culminating event.
The Summit planning committee has selected two legendary leaders to honor this year with the Abbey Meyers Khushi Bridging RARE Award in recognition of their dedicated lifetime of achievements to foster cross-border collaborations in the field of rare genetic and undiagnosed diseases. The two honorees this year are Dr. William A. Gahl, Senior Investigator at the National Human Genome Research Institute, National Institutes of Health, and Padmashri Dr. Ishwar Chander Verma, Senior Advisor at the Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, Delhi. “The U.S. and India possess complementary skillsets and resources in the context of researching and treating rare diseases,” says Dr. Verma upon accepting the award. “Collaboration is the way forward.”
“Dr. Abbey Meyers is a living legend who was instrumental in the enactment of the U.S. FDA Orphan Drug Act of 1983 which has had immense impact in the U.S. and kicked off a global crusade. By honoring these legends who have advanced research in rare and undiagnosed diseases, the Indo US Organization for Rare Diseases together with the Bridging RARE planning committee seeks their vast wisdom and guidance to carry forward the mission of catalyzing cross-border collaborations for patient-focused research and the next generation of affordable orphan drug development.” Says Rajasimha.
About the Bridging RARE Summit: The Bridging RARE Summit 2023 is organized by the Indo US Organization for Rare Diseases, a non-profit organization based in the Biohealth capital region and a platinum member of the National Organization for Rare Diseases (NORD). The main collaborating U.S. and Indian organizations for the 2023 Summit include George Mason University, Virginia BIO, BioHealth Capital Region Forum, All India Institute of Medical Sciences (AIIMS) New Delhi, Centre for DNA Fingerprinting and Diagnostics (CDFD) India, Global Genes, EveryLife Foundation for Rare Diseases, other collaborators and sponsors. For the full agenda, keynote speakers, Gala, Registration, and Sponsorship opportunities, visit https://bridgingrare.org.
About Indo US organization for rare diseases: IndoUSrare is a humanitarian nonprofit 501(c)(3) tax-exempt public charity organization based in the United States. Founder and Executive Chairman Dr. Harsha Rajasimha, who lost a child to a rare disease in 2012, has been a rare disease advocate for more than 10 years. To address the unmet needs of diverse patients with rare diseases globally, the leadership team comprised of experienced professionals from research, advocacy, regulatory, and drug development seeks to build cross-border collaborations connecting stakeholders of rare diseases in low- and middle-income regions such as India, with their counterparts and clinical researchers in the United States to improve the diversity of clinical trial participants, accelerate research and development, and improve equitable access to life-saving therapies to diverse populations of rare disease patients. Visit https://indousrare.org.
References:
Ministry of Health and Family Welfare. “National Policy for Rare Diseases, 2021.” Ministry of Health and Family Welfare, rarediseases.mohfw.gov.in/uploads/Content/1624967837_Final-NPRD-2021.pdf. Accessed 16 Sep. 2023.
Roberts, Alexis-Danielle, Roopma Wadhwa. “Orphan Drug Approval Laws.” National Library of Medicine, ncbi.nlm.nih.gov/books/NBK572052/. Accessed 16 Sep. 2023.
Saltonstall, R.K., Peter L. (2023). The IRA needs changes to better support patients with rare diseases. [online] STAT. Available at: Accessed 9 Oct. 2023.
Scott, R. (2022). Alnylam Opts Against Phase III Trial for Vutrisiran in Stargardt Disease – Updated. [online] BioSpace. Available at: Accessed 9 Oct. 2023.
Salian, Priti. “What price a child’s life? India’s quest to make rare disease drugs affordable.” The Guardian, theguardian.com/global-development/2021/mar/15/what-price-a-childs-life-indias-quest-to-make-rare-disease-drugs-affordable. Accessed 16 Sep. 2023.
Ministry of Health and Family Welfare. “National Policy for Rare Diseases, 2021.” Ministry of Health and Family Welfare, rarediseases.mohfw.gov.in/uploads/Content/1624967837_Final-NPRD-2021.pdf. Accessed 16 Sep. 2023.
Chakraborty, Monoswi et al. “Rare disease patients in India are rarely involved in international orphan drug trials.” PLOS Global Public Health, journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0000890. Accessed 16 Sep. 2023.
Media Contact
Karla Jo Helms, JOTO PR™, 727-777-4619, [email protected], jotopr.com
Guests who indicated struggling with PTSD at baseline (average PCL-5 score = 43.04) showed a large reduction in self-reported PTSD symptoms one month after treatment (average PCL-5 score = 17.90). Evidence suggests that a 5-10 point change in the PCL-5 represents reliable change (not due to chance) and a 10-20 point change represents clinically significant change. The study’s clinically significant reduction in PTSD symptoms among these guests is sustained at the 12-month mark post-retreat.
MycoMeditations operates its Treasure Beach, Jamaica retreat center based on a contemporary psychotherapeutic model, with the majority of the team consisting of licensed therapists. Guests must first complete a thorough medical and psychiatric screening to determine suitability and desired treatment outcomes before being admitted to any MycoMeditations program.
The organization is the first non-research group to widely disseminate for analysis and discussion the results of its psilocybin-assisted therapy protocols leading to positive outcomes in the management of PTSD symptoms. MycoMeditations acknowledges this data is not intended to constitute either an academic study or a clinical trial in its controls, procedure, structure, or review process. Nevertheless, the data is expected to guide future research and to highlight the mental health benefits of psilocybin-assisted treatment for some people with PTSD.
“While clinical trial data are promising and benefit from rigorous controls, these trials can only accept a small subset of individuals and often exclude people that are a more accurate representation of the public at large,” said Justin Townsend, CEO of MycoMeditations. “For example, those who are experiencing multiple mental health conditions, traumatic brain injuries, cognitive issues, and physical health conditions are typically excluded from clinical research. Our data suggest that our psilocybin-assisted retreat model may produce lasting improvements in PTSD symptoms within a broader population at a comparable rate of success.”
MycoMeditations is committed to complete data transparency surrounding these important issues. MycoMeditations team members and therapists, including CEO Justin Townsend, are available for comment.
About MycoMeditations
MycoMeditations operates legal psilocybin-assisted retreats in Jamaica for individuals seeking both therapeutic outcomes and personal growth. As a world leader in the evolving fields of psychedelic therapy and wellness tourism, its success is driven by its commitment to providing safe, life-changing, and spiritually-affirming experiences to its clients in beautiful natural settings. Guided by expert facilitators and mental health professionals, the MycoMeditations team brings together diverse skill sets and a deep knowledge base to create professional and personalized retreats, all while investing in the local Jamaican community. Since 2014, MycoMeditations’ unique psilocybin-assisted retreat protocols have helped over two thousand clients by administering over six thousand doses of therapeutic psilocybin. For more information, please visit MycoMeditations.com.
This strategic alliance offers unique benefits to users by streamlining processes and elevating the comprehensiveness of their international background checks.
“NetForce Global is excited to integrate with TazWorks,” said Jennifer Clark, President of NetForce Global. “Our partnership with TazWorks enhances our commitment to provide customers with robust, reliable, and compliant background check solutions. Together, we’re streamlining the screening process, delivering real value to our clients and the industry as a whole.”
TazWorks is run on TazCloud, a scalable and efficient cloud-based technology platform. The TazWorks platform helps simplify the background screening process through its suite of screening applications. It features screening tools, onboarding and training, identity verification, mobile engagement, decision tools, workload management, and business intelligence.
“Integrated ordering and result reporting for searches outside the United States has been on our wish list for many years. I can’t wait for this partnership between TazWorks and NFG to transform international background screening from some of the most time consuming and onerous work we do to a simple, powerful process,” said Elaine Rosenberg, CEO Advanced Reporting.
For more information about NetForce Global and its suite of solutions, visit info.netforceglobal.com.
About NetForce Global
NetForce Global is the trusted leading wholesaler of international background screenings in the Americas, EMEA and the Asia/Pacific regions. Founded by two industry veterans in 2008, we provide customers with the confidence they need to make better-informed hiring decisions. Dedicated to providing wholesale-only international products and services, NetForce Global is focused on helping retail background screening customers with solutions for virtually all of their international background screening needs. Learn more at info.netforceglobal.com.
About MeridianLink
MeridianLink® (NYSE: MLNK) powers digital lending and account opening for financial institutions and provides data verification solutions for consumer reporting agencies. MeridianLink’s scalable, cloud-based platforms help customers build deeper relationships with consumers through data-driven, personalized experiences across the entire lending life cycle.
MeridianLink enables customers to accelerate revenue growth, reduce risk, and exceed consumer expectations through seamless digital experiences. Its partner marketplace supports hundreds of integrations for tailored innovation. For more than 20 years, MeridianLink has prioritized the democratization of lending for consumers, businesses, and communities. Learn more at http://www.meridianlink.com.
La 11e édition du Sommet WISE explorera les défis et les opportunités de l’IA dans l’éducation DOHA, Qatar, 11 octobre 2023 /PRNewswire/ — Reconnaissant le pouvoir de transformation de l’IA et la façon dont elle devient partie intégrante de notre vie quotidienne, le Sommet WISE 2023…
